Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Short-term Investments (2016 - 2025)

Historic Short-term Investments for RedHill Biopharma (RDHL) over the last 14 years, with Q2 2025 value amounting to $11000.0.

  • RedHill Biopharma's Short-term Investments fell 9956.71% to $11000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $11000.0, marking a year-over-year decrease of 9956.71%. This contributed to the annual value of $1.4 million for FY2024, which is 9176.79% up from last year.
  • Latest data reveals that RedHill Biopharma reported Short-term Investments of $11000.0 as of Q2 2025, which was down 9956.71% from $1.4 million recorded in Q4 2024.
  • RedHill Biopharma's 5-year Short-term Investments high stood at $6.1 million for Q2 2022, and its period low was $11000.0 during Q2 2025.
  • Over the past 4 years, RedHill Biopharma's median Short-term Investments value was $1.6 million (recorded in 2023), while the average stood at $2.2 million.
  • In the last 5 years, RedHill Biopharma's Short-term Investments skyrocketed by 9176.79% in 2024 and then crashed by 9956.71% in 2025.
  • Over the past 4 years, RedHill Biopharma's Short-term Investments (Quarter) stood at $2.6 million in 2022, then crashed by 71.75% to $741000.0 in 2023, then skyrocketed by 91.77% to $1.4 million in 2024, then crashed by 99.23% to $11000.0 in 2025.
  • Its last three reported values are $11000.0 in Q2 2025, $1.4 million for Q4 2024, and $2.5 million during Q2 2024.